Patent intelligence · US
US 8163709
TAK1-D mediated induction of cell death in human cancer cells by specific sequence short double-stranded RNAS
TAK1-D mediated induction of cell death in human cancer cells by specific sequence short double-stranded RNAS
Patent details — US 8163709
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 24, 2012
- Expiration
- Apr 19, 2032
- Claims
- 11
- CPC classes
- A61K, A61K31/7105, A61P, A61P35/00
Quick answer
US 8163709 (TAK1-D mediated induction of cell death in human cancer cells by specific sequence short double-stranded RNAS) is held by The Board of Regents of the University of Texas System. Status: granted. Granted Apr 24, 2012. Expires Apr 19, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/7105, A61P, A61P35/00
More from The Board of Regents of the University of Texas System
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 8163709?
US 8163709 (TAK1-D mediated induction of cell death in human cancer cells by specific sequence short double-stranded RNAS) is held by The Board of Regents of the University of Texas System. Status: granted. Granted Apr 24, 2012. Expires Apr 19, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8163709?
The Board of Regents of the University of Texas System is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 8163709 expire?
Our index shows an expiration date of Apr 19, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.